Regulatory dendritic cell (DCreg)

Regulatory dendritic cells (DCregs), also known as tolerogenic dendritic cells (tolDCs), are a specialized subset of dendritic cells that function to maintain immunological self-tolerance and limit excessive immune responses. Unlike conventional dendritic cells that activate effector T cells, DCregs are characterized by a semi-mature or distinct suppressive phenotype, featuring low levels of costimulatory molecules like CD80 and CD86 and high expression of inhibitory markers such as PD-L1 and IDO. They act by inducing T-cell anergy, promoting the differentiation of regulatory T cells (Tregs), and secreting anti-inflammatory cytokines like IL-10. In clinical medicine, DCregs are primarily viewed as a cellular therapeutic platform rather than a single molecular target. They are currently being investigated in clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, as well as for preventing rejection in organ transplantation and graft-versus-host disease (GvHD). Therapeutic strategies often involve generating these cells ex vivo from a patient's monocytes using pharmacological agents like Vitamin D3 or dexamethasone before re-infusing them to restore immune balance.

Other names

Tolerogenic dendritic celltolDCSuppressive dendritic cellImmature dendritic cell (in specific contexts)Inducible regulatory dendritic cell

Modulation of T-cell responses through the downregulation of costimulatory molecules (CD80, CD86), upregulation of inhibitory ligands (PD-L1, PD-L2), and secretion of immunosuppressive cytokines (IL-10, TGF-beta) to induce T-cell anergy or regulatory T-cell (Treg) differentiation.